STAT

FEBRUARY 8, 2024

People receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray, according to a new study. The new paper , published Thursday in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, showed no significant difference in survival rates between people who were revived using 4- and 8-milligram sprays of naloxone, commonly known by the brand name Narcan.

355

355

PharmaVoice

FEBRUARY 8, 2024

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

130

130

STAT

FEBRUARY 8, 2024

Despite widespread promises of reform after the murder of George Floyd in 2020, in 2023, police killed at least 1,246 people — the most in more than a decade. This police violence is intertwined with a parallel public policy disaster: America’s abysmal mental health systems that force police officers to function as de facto mental health workers.

360

360

pharmaphorum

FEBRUARY 8, 2024

Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.

129

129

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

FEBRUARY 8, 2024

The world may be getting over the idea that men are from Mars and women from Venus , but public perception still holds that testosterone is the male hormone , and estrogen, the female. That can make the following fact a little puzzling: There is more testosterone than estrogen in a premenopausal woman’s body. Testosterone levels decrease with time and reach especially low values after menopause, which can lead to loss of bone density, lower energy, and depression.

317

317

BioPharma Dive

FEBRUARY 8, 2024

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.

112

112

pharmaphorum

FEBRUARY 8, 2024

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.

118

118

STAT

FEBRUARY 8, 2024

Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

340

340

The Pharmacist

FEBRUARY 8, 2024

Nearly 70% of the public would be happy for their medical records to be shared between clinicians, a YouGov poll for The Times Health Commission has found. Its report, published this week, proposed patient record sharing through digital ‘patient passports’ and incentivising pharmacists ‘to do more prescribing, consultations and community care’ to relieve pressure on […] The post Seven in 10 back data sharing between clinicians appeared first on The Pharmacist.

Medical Records 105

Medical Records 105

STAT

FEBRUARY 8, 2024

Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials.

283

283

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Express Pharma

FEBRUARY 8, 2024

Biocon Biologics announced a five-year partnership with Sandoz AG which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD $35 million) and biosimilar Bevacizumab (market value of AUD $45 million) in Australia. Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pha

Biosimilars 104

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 104

STAT

FEBRUARY 8, 2024

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. A looming test for neoantigen cancer vaccines Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that i

Vaccines 283

Vaccines 283

pharmaphorum

FEBRUARY 8, 2024

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.

109

109

STAT

FEBRUARY 8, 2024

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals.

Drug Pricing 274

Drug Pricing Diabetes 274

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

European Pharmaceutical Review

FEBRUARY 8, 2024

Vertex Pharmaceuticals’ once-daily small molecule vanzacaftor/tezacaftor/deutivacaftor (vanza triple) for cystic fibrosis (CF) has gleaned positive results in Phase III trials. The Phase III trials The clinical programme for the once daily vanza triple was comprised of two Phase III trials: SKYLINE 102 and SKYLINE 103, evaluating the efficacy of vanzacaftor (20 mg)/tezacaftor (100 mg)/deutivacaftor (250 mg) in cystic fibrosis patients 12 years and older with at least one F508del mutation or a m

98

98

STAT

FEBRUARY 8, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceutical companies that will be testifying before Sen.

Pharmaceutical Companies 256

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Vaccines 256

Express Pharma

FEBRUARY 8, 2024

Deeptech startup Algorithmic Biologics (AlgoBio) launched the Tapestry platform for next-generation sequencing (NGS) at Genomics India Conference 2024 recently. The company informs that Tapestry empowers genomics labs to cut sequencing costs significantly by eliminating 60 to 90 per cent of library preparation costs that is 33-50 per cent of the total sequencing costs.

102

102

STAT

FEBRUARY 8, 2024

WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared.

Drug Pricing 256

Drug Pricing 256

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

European Pharmaceutical Review

FEBRUARY 8, 2024

A report from Prophecy Market Insights on rapid microbiology testing has predicted that the market is anticipated to surpass $12.7 billion by 2034. Growth drivers of the global rapid microbiology testing market A rise in infectious diseases worldwide has increased demand for rapid and precise diagnostics. This has in turn accelerated growth of this market, the report stated.

Drug Development 98

Drug Development 98

STAT

FEBRUARY 8, 2024

By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies. Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023.

Hospitals 249

Hospitals 249

Express Pharma

FEBRUARY 8, 2024

Zydus Lifesciences has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg (USRLD: Decadron® Tablets) and Dexamethasone Tablets USP, 2 mg (USRLD: Dexamethasone Tablets). Dexamethasone is used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin

101

101

STAT

FEBRUARY 8, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.

Drug Pricing 248

Drug Pricing Drug Development 248

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

FEBRUARY 8, 2024

AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards an FDA BLA.

111

111

Outsourcing Pharma

FEBRUARY 8, 2024

With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.

Independent Pharmacies 101

Independent Pharmacies 101

pharmaphorum

FEBRUARY 8, 2024

Stay up to date with the latest updates in the world of clinical trials. This week's highlights include Bayer's new study on aflibercept, BioNTech's groundbreaking research, and the exciting developments from Duality Bio. Get all the important information here.

104

104

Outsourcing Pharma

FEBRUARY 8, 2024

Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.

98

98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

FEBRUARY 8, 2024

BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies

105

105

Pharma Times

FEBRUARY 8, 2024

The committee has advised that the vaccine should be given to those at the highest risk

Vaccines 122

Vaccines 122

pharmaphorum

FEBRUARY 8, 2024

Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team

105

105

Express Pharma

FEBRUARY 8, 2024

Agilent India has been honoured with the Best Bioprocessing Supplier Award: Analytical Services at the Biopharma Excellence Awards (BEA) 2024. These prestigious awards, organized by IMAPAC, recognize organizations and technologies that contribute to vaccine research and development (R&D) and biologics manufacturing excellence in developing economies, particularly India.

Research Laboratories 93

Research Laboratories Vaccines 93

pharmaphorum

FEBRUARY 8, 2024

Autoimmune disease CAR-T therapy specialist Kyverna has upsized its IPO to $319m in another sign of an improving #biotech financing environment

105

105